CYP1B1
MOLECULAR TARGETcytochrome P450 family 1 subfamily B member 1
CYP1B1 (cytochrome P450 family 1 subfamily B member 1) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CYP1B1
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Quercetin | 2.20 | 8 |
| 2 | chrysin | 2.08 | 7 |
| 3 | Apigenin 5,7,4'-trihydroxy-flavone, | 1.61 | 4 |
| 4 | Berberine | 1.61 | 4 |
| 5 | Luteolin 5,7,3',4'-tetrahydroxy-flavone, | 1.61 | 4 |
| 6 | pterostilbene | 1.39 | 3 |
| 7 | Resveratrol | 1.39 | 3 |
| 8 | isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from | 1.39 | 3 |
| 9 | Kaempferols | 1.10 | 2 |
| 10 | myricetin-3-O-galactopyranoside [Supplementary Concept] | 1.10 | 2 |
| 11 | Carvedilol | 1.10 | 2 |
| 12 | cbd | 0.69 | 1 |
| 13 | Kaempferols | 0.69 | 1 |
| 14 | plumbagin [Supplementary Concept] | 0.69 | 1 |
| 15 | cannabidiol | 0.69 | 1 |
| 16 | Emodin Purgative anthraquinone found in several plants, especially RHAMNUS PURSHIANA. It was formerly used as | 0.69 | 1 |
| 17 | Hesperidin | 0.69 | 1 |
| 18 | scutellarein | 0.69 | 1 |
| 19 | tamarixetin | 0.69 | 1 |
About CYP1B1 as a Drug Target
CYP1B1 (cytochrome P450 family 1 subfamily B member 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented CYP1B1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CYP1B1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.